Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT06046742

A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors

Led by Guangzhou Virotech Pharmaceutical Co., Ltd. · Updated on 2025-03-13

12

Participants Needed

3

Research Sites

127 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A Phase I Study of the Safety and Tolerability of M1-c6v1 Administered Via Intravenously for Treatment of Patients With Locally Advanced or Metastatic Solid Tumors

CONDITIONS

Official Title

A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of locally advanced or metastatic solid tumors intolerant or refractory to standard therapy
  • Voluntary agreement to participate and signed informed consent before screening
  • Male or female aged 18 years or older at screening
  • At least one measurable tumor lesion
  • ECOG performance status of 0 or 1 within 1 week before first dose
  • Estimated survival time of at least 12 weeks
Not Eligible

You will not qualify if you...

  • History of immunodeficiency, leukemia, lymphoma, AIDS, or HIV infection or immunosuppressive therapy
  • Received any anti-tumor treatment within 4 weeks before first study drug administration
  • Taken systemic glucocorticoids over 10 mg/day or similar immunosuppressive drugs within 14 days before first dose
  • Received immunomodulatory drugs such as thymosin, IL-2, or interferon within 14 days before first dose

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

National Cancer Center Hospital East

Kashiwa-shi, Chiba, Japan

Actively Recruiting

2

National Hospital Organization Shikoku Cancer Center

Matsuyama, Ehime, Japan

Actively Recruiting

3

St. Marianna University Hospital

Kawasaki-shi, Kanagawa, Japan

Actively Recruiting

Loading map...

Research Team

G

Guangzhou Virotech Pharmaceutical Co., Ltd.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here